ES2524894T3 - Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe - Google Patents
Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe Download PDFInfo
- Publication number
- ES2524894T3 ES2524894T3 ES11781731.2T ES11781731T ES2524894T3 ES 2524894 T3 ES2524894 T3 ES 2524894T3 ES 11781731 T ES11781731 T ES 11781731T ES 2524894 T3 ES2524894 T3 ES 2524894T3
- Authority
- ES
- Spain
- Prior art keywords
- influenza virus
- permanent human
- cell line
- human amniocyte
- virus production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un procedimiento de producción de una vacuna a base de virus de la gripe, que comprende: a) infectar un amniocito humano permanente con un virus de la gripe; b) cultivar el amniocito humano permanente; c) expresar el virus de la gripe; y d) aislar el virus de la gripe del medio, en el que el amniocito humano permanente expresa los productos génicos adenovirales E1A y E1B.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010037008 | 2010-08-16 | ||
DE102010037008 | 2010-08-16 | ||
DE102011050353 | 2011-05-13 | ||
DE102011050353 | 2011-05-13 | ||
PCT/DE2011/075194 WO2012041311A1 (de) | 2010-08-16 | 2011-08-16 | Permanente humane amniozyten zelllinie zur herstellung von influenzaviren |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2524894T3 true ES2524894T3 (es) | 2014-12-15 |
Family
ID=44936126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11781731.2T Active ES2524894T3 (es) | 2010-08-16 | 2011-08-16 | Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe |
Country Status (19)
Country | Link |
---|---|
US (1) | US20130344569A1 (es) |
EP (1) | EP2606128B1 (es) |
JP (1) | JP5928843B2 (es) |
KR (1) | KR101780257B1 (es) |
CN (1) | CN103168100B (es) |
AU (1) | AU2011307655B2 (es) |
BR (1) | BR112013003766B1 (es) |
CA (1) | CA2808453C (es) |
DE (1) | DE112011102737A5 (es) |
DK (1) | DK2606128T3 (es) |
ES (1) | ES2524894T3 (es) |
IL (1) | IL224728A (es) |
MX (1) | MX337687B (es) |
PL (1) | PL2606128T3 (es) |
PT (1) | PT2606128E (es) |
RU (1) | RU2565546C2 (es) |
SG (1) | SG187863A1 (es) |
TW (1) | TW201211257A (es) |
WO (1) | WO2012041311A1 (es) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US20050170463A1 (en) * | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
DE19955558C2 (de) * | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
EP1831353B1 (en) * | 2004-12-23 | 2012-02-29 | MedImmune, LLC | Non-tumorigenic mdck cell line for propagating viruses |
US8354114B2 (en) * | 2005-10-17 | 2013-01-15 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
DE102005054628A1 (de) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
SG174813A1 (en) * | 2006-09-15 | 2011-10-28 | Medimmune Llc | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
-
2011
- 2011-08-16 WO PCT/DE2011/075194 patent/WO2012041311A1/de active Application Filing
- 2011-08-16 SG SG2013011499A patent/SG187863A1/en unknown
- 2011-08-16 CN CN201180050018.7A patent/CN103168100B/zh active Active
- 2011-08-16 US US13/816,976 patent/US20130344569A1/en not_active Abandoned
- 2011-08-16 RU RU2013110786/10A patent/RU2565546C2/ru active IP Right Revival
- 2011-08-16 CA CA2808453A patent/CA2808453C/en active Active
- 2011-08-16 TW TW100129162A patent/TW201211257A/zh unknown
- 2011-08-16 AU AU2011307655A patent/AU2011307655B2/en active Active
- 2011-08-16 KR KR1020137006640A patent/KR101780257B1/ko active IP Right Grant
- 2011-08-16 DE DE112011102737T patent/DE112011102737A5/de not_active Withdrawn
- 2011-08-16 EP EP11781731.2A patent/EP2606128B1/de active Active
- 2011-08-16 ES ES11781731.2T patent/ES2524894T3/es active Active
- 2011-08-16 PL PL11781731T patent/PL2606128T3/pl unknown
- 2011-08-16 DK DK11781731.2T patent/DK2606128T3/en active
- 2011-08-16 PT PT117817312T patent/PT2606128E/pt unknown
- 2011-08-16 BR BR112013003766-0A patent/BR112013003766B1/pt active IP Right Grant
- 2011-08-16 MX MX2013001772A patent/MX337687B/es active IP Right Grant
- 2011-08-16 JP JP2013524350A patent/JP5928843B2/ja active Active
-
2013
- 2013-02-14 IL IL224728A patent/IL224728A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2013110786A (ru) | 2014-09-27 |
CN103168100B (zh) | 2016-04-13 |
TW201211257A (en) | 2012-03-16 |
KR101780257B1 (ko) | 2017-09-21 |
CA2808453C (en) | 2020-05-05 |
JP5928843B2 (ja) | 2016-06-01 |
KR20130097191A (ko) | 2013-09-02 |
EP2606128B1 (de) | 2014-09-10 |
BR112013003766B1 (pt) | 2021-08-24 |
PT2606128E (pt) | 2014-12-09 |
US20130344569A1 (en) | 2013-12-26 |
EP2606128A1 (de) | 2013-06-26 |
WO2012041311A1 (de) | 2012-04-05 |
PL2606128T3 (pl) | 2015-02-27 |
CA2808453A1 (en) | 2012-04-05 |
MX2013001772A (es) | 2013-06-03 |
AU2011307655B2 (en) | 2015-12-17 |
RU2565546C2 (ru) | 2015-10-20 |
SG187863A1 (en) | 2013-03-28 |
IL224728A (en) | 2016-05-31 |
DE112011102737A5 (de) | 2013-06-06 |
BR112013003766A2 (pt) | 2016-05-31 |
CN103168100A (zh) | 2013-06-19 |
MX337687B (es) | 2016-03-15 |
JP2013537543A (ja) | 2013-10-03 |
AU2011307655A1 (en) | 2013-03-21 |
DK2606128T3 (en) | 2014-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2621264T3 (es) | Cepa de Bifidobacterium animalis ssp. animalis | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
EA201300915A1 (ru) | Новый европейский штамм prrsv | |
CR20150170A (es) | Vacunas de inmersión subunidad para peces | |
ES2613400T3 (es) | Método para mejorar la fagocitosis de células que exponen fosfatidilserina | |
JP2011004745A5 (es) | ||
UY33856A (es) | ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?. | |
JP2012098270A5 (es) | ||
AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
ES2524894T3 (es) | Línea celular de amniocitos humanos permanentes para la producción de virus de la gripe | |
ES2565198T3 (es) | Metapneumovirus aviar en oncólisis | |
Дроздова et al. | The Keys. English Grammar | |
ES2560329T3 (es) | Procedimiento de transformación de iota-carragenano en alfa-carragenano por medio de una clase novedosa de 4S-iota-carragenano sulfatasa | |
RU2011140186A (ru) | Галогенсодержащие ароматические полиэфиры | |
CU24328B1 (es) | Método para la generación de una cadena rotavirus humana atenuada rv3 en células vero | |
ES2478692A1 (es) | Formulaciones líquidas de carbocisteína de propiedades mejoradas | |
WO2015071763A3 (en) | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof | |
RU2010121552A (ru) | Штамм bifidobacterium longum гв-9, используемый для получения бифидосодержащей продукции | |
RU2010121553A (ru) | Штамм bifidobacterium bifidum 74-23, используемый для получения бифидосодержащей продукции | |
RU2010119250A (ru) | Штамм bifidobacterium adolescentis рвв-1, используемый для получения продукции | |
RU2011116802A (ru) | 1-(1-адамантил)-4-нитрозопиразолы | |
RU2010119255A (ru) | Штамм bifidobacterium adolescentis 79-82, используемый для получения бифидосодержащей продукции | |
TH121338S (th) | เครื่องดูดฝุ่น | |
Дроздова et al. | The Keys. English Grammar: Reference and Practice. Version 2.0 |